ArticleJournal of diabetes2026
Circulating SCGB3A2 Is Associated With Impaired Coronary Collateralization in Patients With Chronic Total Occlusion and Type 2 Diabetes: A Proteomic Discovery and Validation Study.
Article in Journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) is associated with impaired coronary collateralization in patients with chronic total occlusion (CTO), but circulating biomarkers reflecting defective collateral remodeling remain poorly defined.
methodsOlink proteomic profiling was performed in a discovery cohort of 88 CTO patients with T2DM stratified by collateral status. Candidate proteins were prioritized using nominal differential expression and partial least squares-discriminant analyses. Secretoglobin family 3A member 2 (SCGB3A2) was selected for validation by ELISA in an independent cohort of 832 CTO patients (425 with T2DM and 407 without diabetes). Associations with collateralization and incremental predictive value beyond clinical risk factors were evaluated.
resultsAmong 265 proteins, eight showed nominal differential expression, with SCGB3A2 exhibiting the strongest signal and highest variable importance. In the T2DM cohort, serum SCGB3A2 levels were significantly higher in patients with poor collateralization and inversely correlated with Rentrop grades (both p < 0.001). SCGB3A2 remained independently associated with poor collateralization after multivariable adjustment (OR per 10 ng/mL increase, 1.63; 95% CI, 1.39-1.94; p < 0.001). Addition of SCGB3A2 to a clinical model improved discrimination with an increase in C-statistic from 0.73 to 0.78 and reclassification (NRI 0.62; IDI 0.08). Similar associations were observed in patients without diabetes.
conclusionsCirculating SCGB3A2 is independently associated with impaired coronary collateralization in CTO patients. It may reflect biological processes underlying collateral failure and improve risk stratification, particularly in patients with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.